Abstract:Objective: To compare the curative effects and adverse reactions between cisplatin- and carboplatin-based third generation chemotherapies in the treatment of patients with stage IIIB/IV squamous cell lung cancer. Methods: To review 6 112 clinical records between June 2002 and May 2009 to identify 299 patients who had advanced squamous cell lung cancer and met the inclusion criteria. They were divided into two groups. Group A (n = 225) received cisplatin-based third generation chemotherapy and group B (n = 74) received carboplatin-based third generation chemotherapy. The chemotherapy was repeated every 21 d and the curative effects were evaluated after two cycles and were determined after 4 cycles. The primary end-point index was overall survival (OS) and the secondary end-point parameters were response rate (RR) and adverse reactions. Results: RR were 31.1% (70/225) and 28.4% (21/74) for group A and group B, respectively. The difference was not significant (P = 0.658). The OS was more prolonged in group A than that in group B. The median survival time (MST) was 328 d for group A and 259 d for group B (P = 0.012, HR =0.754, P = 0.041). The 1-year survival rate in group A was higher than that in group B [48.9% (110/225) vs 31.1% (23/74), OR = 2.121, P = 0.008]. Subgroup analysis demonstrated that for the patients at stage IIIB the OS was more prolonged in the group A than that in group B. The MST were 347 and 302 d, respectively (P = 0.027; HR = 0.663, P = 0.001). For the patients at stage IV the OS tended to be prolonged in group A compared with group B but the difference was not significant. The MST were 282 d and 253 d, respectively (P = 0.152; HR = 0.859, P = 0.245 ). Multivariate analysis showed that clinical stage and gender were independent prognostic factors. Patients at stage IIIB (HR = 0.879, P = 0.025) and female patients (HR = 1.278, P = 0.001) had better prognosis. Age was not related with the prognosis (HR = 0.956, P = 0.565). The incidence rate of grade III to IV thrombocytopenia in group B was higher than that in group A (16.2% vs 7.1%, P = 0.020), whereas the incidence rate of gastrointestinal reaction such as nausea and vomiting was significantly decreased in group B compared with group A (5.4% vs 16.9%, P = 0.014). Conclusion: Cisplatin-based or carboplatin-based third generation chemotherapy had similar response rate in the treatment of advanced squamous lung cancer patients with higher PS score especially for those at IIIB stage. But patients who received cisplatin-based third generation chemotherapy had higher overall survival rate. The gastrointestinal adverse reactions such as nausea and vomiting occurred more frequently.

Meta-Analysis Comparing Carboplatin and Cisplatin-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer.

Efficacy of Pemetrexed Plus Platinum Doublet Chemotherapy As First-Line Treatment for Advanced Nonsquamous Non-Small-cell-lung Cancer: a Systematic Review and Meta-Analysis.

A Meta-analysis of Cisplatin Versus Carboplatin Based Third-Generation Chemotherapy in First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Comparison of Cisplatin-Mitomycin-vinorelbine Versus Cisplatin-Mitomycin-vindesine Regimen for Treatment of Advanced Non-Small Cell Lung Cancer: a Report of 83 Patients

Efficacy of Third‐generation Chemotherapeutic Agents Combined with Cisplatin or Carboplatin in 3100 Chinese Patients with Advanced Non‐small‐cell Lung Cancer

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Comparison of Gemcitabine/carboplat in Versus Paclitaxel/cisplatin for the Management of Non Small Cell Lung Cancer

Meta-analysis of comparing nedaplatin-containing chemotherapy with cisplatin-containing chemotherapy in the treatment of advanced non-small cell lung cancer

[Comparison of Cisplatin Combined with Gemcitabine Versus Cisplatin Combined with Vinorelbine Regimen for Treatment of Patients with Advanced Non-Small Cell Lung Cancer].

Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer

Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

Cisplatin/carboplatin-based third generation chemotherapy in the treatment of 299 patients with advanced squamous cell lung cancer: a clinical study

Comparison between cisplatin plus vinorelbine and cisplatin plus docetaxel in the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials.

[A Meta-Analysis of Pemetrexed Plus Platinum Chemotherapy Versus Gemcitabine Plus Platinum Chemotherapy for Advanced Non-Small Cell Lung Cancer].

A Meta Analysis of Gemcitabine Plus Platinum Chemotherapy Compared with Single-agent Chemotherapy in the Treatment of Non-small Cell Lung Cancer

Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer

Gemcitabine Plus Paclitaxel Versus Carboplatin Plus Either Gemcitabine or Paclitaxel in Advanced Non-small-cell Lung Cancer: A Literature-based Meta-analysis

Investigation of the Optimal Platinum-Based Regimen in the Postoperative Adjuvant Chemotherapy Setting for Early-Stage Resected Non-Small Lung Cancer: a Bayesian Network Meta-Analysis

Comparing Single‐agent with Doublet Chemotherapy in First‐line Treatment of Advanced Non‐small Cell Lung Cancer with Performance Status 2: A Meta‐analysis